Jim Cramer is still ‘crazy’ about these stocks

Jim Cramer, the Mad Money host and former hedge fund manager, is known for his hot financial takes, but some of his latest investment recommendations might still surprise you. 

Here, we’ve covered two relatively underlooked stocks Cramer is still crazy about, based on his investment club discussions over the past few days.

Procter & Gamble (PG)

During the December 16 episode of Mad Money, Cramer singled out Procter & Gamble (NYSE: PG) as his favorite tech stock right now:

The American multinational consumer goods corporation, Cramer noted, spends more than $2 billion a year on developing new products, acting as a “House of Innovation.” 

Procter & Gamble, which owns household staples such as Pampers, Gillette, and Mr. Clean, is down nearly 13% year-to-date (YTD), but the investor argued it’s nothing more than a de-risk.

Elaborating further, he drew a clear line between companies that use technology and those that make it, the so-called hyperscalers that pour billions into the most recent trends just to outspend one another.

Right now, those trends revolve around artificial intelligence (AI), and according to Cramer, the Cincinnati firm has successfully employed it to fix its supply chain and save millions of dollars. Therefore, Cramer believes PG and its peers will have a chance to buy “amazing tech that will help them cut costs” and “bring new products to market much faster than ever.”

Danaher (DHR)

As part of his monthly club meeting, Cramer focused his attention on Danaher (NYSE: DHR) on December 15 as “one of 7 out-of-favor stocks to buy.”

After a long stretch of generally negative performance, Carme said, the healthcare stock looks “ready to go for a romp.” 

Danaher, which supplies tools and technologies to pharmaceutical, biotech, and medical device companies, has struggled in the post-Covid period, but it’s been recovering over the past six months, gaining more than 12%.

Wells Fargo acknowledged the recovery, lifting its Danaher price target to $240 from $230 and expecting more organic growth across the life sciences tools industry next year.

Cramer, who had in the past hinted at his frustration with the company, accordingly argues that now is a good time to buy, especially if the price drops again.

Featured image via Shutterstock